Cetyl Alcohol

Cetyl Alcohol

SCHEMBL3813719

C/C=C/C=C/C(=O)O.CCCCCCCCCCCCCCCCO

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PTPN1 P18031 2/20 0.46
ACHE P22303 1/20 0.46
BACE1 P56817 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
HCAR2 Q8TDS4 3/20 0.43
KDM4E B2RXH2 1/20 0.38
GPR84 Q9NQS5 2/20 0.38
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
PPARA Q07869 2/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
SLC22A8 Q8TCC7 1/20 0.38
TLR2 O60603 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cetyl Alcohol SCHEMBL3813721 1.00 LMNA (0.48) LMNAALDH1A1TSHRHSD17B10MEN1
Dodecanol SCHEMBL27448108 1.00 LMNA (0.48) LMNAALDH1A1TSHRHSD17B10MEN1
Sorbic Acid SCHEMBL27992236 0.92 ACHE (0.49) LMNAALDH1A1TSHRHSD17B10MEN1
Sorbic Acid SCHEMBL13734143 0.92 ACHE (0.52) ALDH1A1TSHRHSD17B10MEN1KMT2A
Sorbic Acid SCHEMBL13734145 0.92 ACHE (0.52) ALDH1A1TSHRHSD17B10MEN1KMT2A
Sorbic Acid SCHEMBL28249602 0.92 GPR84 (0.39) LMNAALDH1A1TSHRHSD17B10MEN1
Sorbic Acid SCHEMBL28536418 0.90 ACHE (0.40) TSHRPTPN1ACHEBACE1HCAR2
Decanol SCHEMBL9136433 0.86 TSHR (0.54) LMNAALDH1A1TSHRHSD17B10MEN1
Sorbic Acid SCHEMBL28468693 0.86 ACHE (0.40) TSHRPTPN1ACHEBACE1HCAR2
Sorbic Acid SCHEMBL9156387 0.86 ACHE (0.53) PTPN1ACHEBACE1HCAR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107308130-B Coated drug spheroids and use to eliminate or reduce conditions such as emesis and diarrhea 惠氏有限责任公司 2021-06-15 CN disclosed
CN-106074445-B The purposes of the drug of illness is eliminated or is reduced in coated drugs orbicule and its preparation 惠氏有限责任公司 2018-12-21 CN disclosed
CN-107441058-A Coated drugs orbicule and elimination reduce illness such as the purposes vomitted and suffered from diarrhoea 惠氏有限责任公司 2017-12-08 CN disclosed
CN-107308130-A Coated drugs orbicule and elimination reduce illness such as the purposes vomitted and suffered from diarrhoea 惠氏有限责任公司 2017-11-03 CN disclosed
US-8765717-B2 Meloxicam and glucosamine formulation and uses thereof MONTE VERDE S.A. (AR) 2014-07-01 US disclosed
US-20100004200-A1 MELOXICAM AND GLUCOSAMINE FORMULATION AND USES THEREOF MONTE VERDE S.A. (AR) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004200-A1 MELOXICAM AND GLUCOSAMINE FORMULATION AND USES THEREOF MGAM, FUT6, CSGALNACT1 LMNA 1913/4885ALDH1A1 2248/4885TSHR 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.